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Microbial agents are regarded as a potential cause of tumors, but their direct effects on tumors, such as myeloma, are not well
studied. Our studies demonstrated that expression of HLA-DR and CD40 on the myeloma cell membrane surface is upregulated by
interferon-g and/or microbial antigens (Ags). Unlike prior studies, our study showed that Th2 cells cannot promote myeloma growth
directly. However, Bacillus Calmette–Guerin Vaccine (BCGV)-speciﬁc Th2 cells stimulated by BCGV-loaded dendritic cells (DCs)
promoted myeloma clonogenicity directly when the myeloma cells expressed major histocompatibility complex Class-II molecules
(MHC-II) and took up BCGV Ag. B-cell lymphoma 6 (Bcl-6) protein expression and the proportion of HLA-DR
þ or CD40
þ cells were
higher in colonies of Th2 cell-stimulated myeloma cells. Furthermore, anti-HLA-DR or neutralizing CD40 antibody could prevent this
increase in Bcl-6 expression and colony number. These results indicate that microbes and microbial Ag-speciﬁc Th2 cells may
directly impact the biology of myeloma and contribute to tumor progression. Activation may be limited to MHC-II
þ myeloma cells
that retain B cell and stem cell characteristics. Taken together, our data suggest that factors involved in microbial Ag presentation,
such as DCs, Th2 cells and so on, are potential targets for myeloma therapeutic intervention.
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INTRODUCTION
Th2 cells are an important subset of antigen (Ag)-speciﬁc T cells.
Several studies suggest that Th2 activation by tumor Ags may be
a risk factor for multiple myeloma (MM).
1,2 Prior research has
shown that the Th2 response can promote MM progression after
idiotype-based immunotherapy.
3 Thus, Th2 cells may have the
ability to induce tumor development. However, myeloma cells
express almost no major histocompatibility complex Class-II
molecules (MHC-II), leaving open the question about whether
Th2 cells can directly promote MM progression. Moreover, the
question of whether Th2 cells interact directly with myeloma cells
or impact the biology of myeloma cells has not been answered.
Dendritic cells (DCs) are the most efﬁcient Ag presenting cells
(APCs) and can be used in Ag-based immunotherapy to activate
all T-cell subsets.
3,4 When naı ¨ve T cells are stimulated by a Th2-
inducing Ag, they acquire the ability to interact with B cells that
have speciﬁcally taken up Ag.
5,6 Interaction of DCs with B cells
may also affect B-cell survival.
6,7 Prior studies have shown a
correlation between increased inﬁltration of human tumors by
DCs and adverse prognosis.
8–10 Moreover, it has been demon-
strated in vitro that interaction with DCs can directly enhance
clonogenicity of human MM.
11 Considering that MM is a B-cell
malignancy and Th2 cell–B-cell interaction is crucial for regulating
B-cell function, we supposed that Ag-speciﬁc Th2 cells induced
by DCs would promote the survival and growth of myeloma cells
that express MHC-II molecules and take up the same Ag.
Previous studies have shown that persistence of microbial
Ags in the host is an important growth stimulus for some kinds
of tumor,
12–14 but the pathogenesis of these tumors is still largely
unknown. DC–Th2–B-cell interactions with microbial Ags stimu-
late humoral immunity, which ends in B-cell differentiation into
plasma cells that produce and secrete speciﬁc antibodies to these
Ags.
6 Malignant plasma cells also clonally produce and secrete a
speciﬁc immunoglobulin (Ig). However, it is not known whether
the monoclonal Igs of myeloma cells are speciﬁc for microbial Ags
and whether speciﬁc Ags can promote the growth of malignant
plasma cells as well as the secretion of monoclonal Igs. Therefore,
we hypothesized that microbial Ags presented by APCs may
be an important aspect of myeloma pathogenesis, which we
propose occurs in a multi-step process. First, speciﬁc microbial Ags
presented to Th2 cells by DCs may persist within DCs or Th2 cells.
Then, the speciﬁc Th2 cells may stimulate speciﬁc monoclonal B
cells to proliferate and secrete monoclonal Ig over a long period.
Finally, the speciﬁc B cells may be transformed to malignant
plasma cells, and the speciﬁc Ag may continue to promote the
growth of malignant plasma cells generated by DC–Th2 cell–
myeloma cell interaction.
MATERIALS AND METHODS
Healthy donor samples, patient samples and human myeloma cell
lines
Peripheral blood from healthy donors and bone marrow aspirates from
21 patients with MM (Supplementary Tables 1 and 2) were collected after
they gave their informed consent, which was obtained in accordance with
the Declaration of Helsinki, and after the study protocol was approved by
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University. The human myeloma cell line U266 was kindly provided by
Dr Yang Xu (Suzhou University, Jiangsu, China). The K562 cell line was from
the American Type Culture Collection (ATCC, Manassas, VA, USA). Some U266
cells were treated with interferon-g (IFN-g) (Shanghai Prime Gene Bio-Tech
Co., Shanghai, China) and Bacillus Calmette–Guerin Vaccine (BCGV) for 48h.
Generation of monocyte-derived DCs
Monocyte-derived DCs were generated from peripheral blood monocytes
(PBMCs) using an adaptation of protocols described previously.
15 In brief,
PBMCs were isolated from freshly collected heparin-treated blood
by density gradient centrifugation. Subsequently, 5 10
6cells/ml was
cultured for 2–4h to permit cell adherence, and nonadherent cells
were removed. The adherent cells were cultured 5–7 days in RPMI-1640
complete medium supplied with 20ng/ml of human recombinant granulo-
cyte macrophage colony-stimulating factor (Shanghai Prime Gene Bio-Tech
Co.) and 20ng/ml of interleukin 4 (IL-4; Shanghai Prime Gene Bio-Tech Co.).
TNF-a (Shanghai Prime Gene Bio-Tech Co.) and BCGV were added to the
culture for an additional 48h. For some experiments, maturation to DCs
was stimulated using puriﬁed protein derivative of M. tuberculosis or
tetanus toxoid Ag (TTA) instead of BCGV. The purity of mature DCs in vitro
was at least 95%, which was conﬁrmed for each experiment.
Isolation of BCGV-speciﬁc Th2 (BCGV-Th2) cells
The nonadherent cells removed from PBMCs served as T cells. BCGV-
loaded DCs were added to the T cells at a ratio of 1:30 in the presence
of granulocyte macrophage colony-stimulating factor (20ng/ml), IL-4
(20ng/ml) and IL-2 (10ng/ml; PeproTech, Rocky Hill, NJ, USA). After 5–7
days, BCGV-Th2 cells were isolated using CD4
þ and CD294
þ (CRTH2)
microbeads (Miltenyi Biotec, GmbH, Bergisch Gladbach, Germany) from the
DC–T-cell coculture system according to the manufacturer’s instructions.
16
The purity of Th2 cells (CRTH2) was always 495%.
Clonogenic assays induced by Th2 cells
BCGV-Th2 cells were added to tumor cells at a ratio of 10:1 (tumor cells:
10000/well), mixed completely and cocultured for 48h. The clonogenic
growth of tumor cell lines was evaluated by plating tumor cells in quad-
ruplicate 35-mm
2 tissue culture dishes containing RPMI-1640 complete
medium with 0.9% methylcellulose, 30% fetal bovine serum, 2mM
l-glutamine and 20mg/ml gentamycin sulfate and incubating these
dishes at 371C in a 5% CO2 atmosphere. Colonies consisting of 440 cells
were counted under a microscope 2–3 weeks after plating.
MHC restriction and neutralizing CD40 on U266 cells
To study the role of MHC-II and CD40 molecules in Th2 cell and MM cell
interactions, cells were incubated with mouse MoAb against HLA-DR
(IgG2b; 1mg/ml; Millipore, Billerica, MA, USA), mouse MoAb against CD40
(IgG2b; 5mg/ml; R&D Systems, Minneapolis, MN, USA), or control IgG2b
(5mg/ml), respectively.
17 To assess the Th2-cell contact dependence of
tumor cell clonogenicity, Transwell polyester membrane inserts (CLS3460,
Corning, Inc., Corning, NY, USA) separating U266 cells from BCGV-Th2 cells
were compared with control inserts separating U266 cells from complete
RPMI-1640 medium only.
Clonogenic assay of primary tumor cells
Mononuclear cells (MNCs) isolated from bone marrow samples using
density gradient centrifugation were treated with IFN-g and BCGV for
2 days. Then CD138
þ and CD138
  fractions were isolated from treated-
MNCs using CD138 microbeads (Miltenyi Biotec) and an AutoMACS
magnetic cell sorter (Miltenyi Biotec). The CD138
  fraction was further
depleted of normal hematopoietic progenitors using CD34, CD3, CD4 and
CD8 microbeads (Miltenyi Biotec). The resulting two fractions (CD138
þ
CD34
 CD3
 CD4
 CD8
  and CD138
  CD34
 CD3
 CD4
 CD8
  cells;
0.5–2.5 10
5/ml) were plated with or without BCGV-Th2 cells at a ratio
of 1:2–5 in a methylcellulose culture system (Methocult, Vancouver, BC,
Canada), as described above for U266 cells, containing rhIL-6 (10ng/ml,
PeproTech). Tumor colonies were counted after 2–3 weeks of culture. The
phenotype of the cells in these colonies was conﬁrmed by ﬂow cytometry.
Flow cytometry analysis
Forward scatter on ﬂow cytometry was used to measure tumor cell size
and the change in surface expression of CD80, CD40, HLA-DR, intracellular
l light chain and so on. Data were collected and analyzed using a
FACScalibur ﬂow cytometer and Cell Quest software (BD Biosciences,
San Jose, CA, USA).
Western blotting
Western blotting was performed on cell lysates from U266 cells. Cells were
lysed with sodium dodecyl sulfate (SDS) loading buffer, and an aliquot of
each lysate was loaded onto an 10% SDS polyacrylamide gel. After
electrophoresis, the proteins in the gel were electrotransferred to
nitrocellulose sheets, probed for 2h with primary antibody to B-cell
lymphoma 6 (Bcl-6) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
diluted 1/500 in PBS-T, 5% milk (Santa Cruz Biotechnology) at room
temperature, washed three times with PBS-T, incubated with secondary
antibody for 1h at room temperature, washed with PBS-T three times,
dried, incubated with enhanced chemiluminescence reagent (Santa Cruz
Biotechnology) for 1min and visualized in a Kodak Imager (Kodak Film,
Kodak, Rochester, NY, USA).
SYBR green PCR assay
RNA was extracted using the Trizol kit (Invitrogen, Carlsbad, CA, USA) and
reverse transcribed into ﬁrst-strand cDNA using random hexamer primers
and a reverse transcriptase Superscript II Kit (Invitrogen), according to
the manufacturer’s instructions. Bcl-6 was produced from Bcl-6-positive
samples by PCR ampliﬁcation, separated on gel and detected. Then, the
target band of Bcl-6 was cut, viewed under long-wave UV, extracted from
the gel, puriﬁed using a QIAquick Gel Extraction Kit (Qiagen, Hilden,
Germany) and used as the positive control (OD 260/28041.8). Sterile
distilled water was used as the negative control. The samples were
ampliﬁed and quantiﬁed on a sequence detection system (API 7500;
Applied Biosystems, Foster City, CA, USA) using the following thermal
cycler conditions: 3min at 931C, 30s at 931C, 45s at 551C, 45s at 721C
and 40 cycles. b-actin, a housekeeping gene, was used to normalize each
sample. The data were analyzed using the API 7500.
Primers were as follows: Bcl-6, F: 50-CAGATTTGTACAGGTGGCCCA-30;
R: 50-AGAGTCTGAAGGTGCCGGAA-30; b-actin, F: 50-GCA TGG GTC AGA AGG
ATT CCT-30;R :5 0-TCG TCC CAG TTG GTG ACG AT-30.
Statistical analysis
Differences between groups were assessed using the Student’s t-test or
one-way analysis of variance for multiple comparisons test. The signi-
sﬁcance level was set at Po0.05.
RESULTS
Change in expression of surface markers on U266 cells and
primary myeloma cells
Treatment with IFN-g for 48h markedly increased surface
expression of HLA-DR, CD40 and CD80, but CD40 and CD80
expression were at a low levels, and CD86 and CD54 (markers
indicating that Th2 cells have the ability to activate B cells)
remained at a high level (Figure 1a). Interestingly, exogenous Ags,
such as BCGV, clearly upregulated HLA-DR and CD40 expression
(Figure 1b). Similar results were also observed in primary myeloma
cells (Table 1). Therefore, exogenous Ag can directly alter the
expression of surface molecules on MM cells, which suggests the
possibility that MM cells can be activated by Th2 cells.
Stimulation of clonogenic growth of U266 cells by Th2 cells
To assess whether U266 cells can respond to Th2 cells, IFN-g and
BCGV-treated U266 cells (treated-U266 cells) were cultured 5 days
in the presence of BCGV-speciﬁc Th2 cells (BCGV-Th2 cells).
Colorimetric assays showed that BCGV-Th2 cells weakly stimulated
the proliferation of treated-U266 cells, but clonogenic assays
showed that BCGV-Th2 cells signiﬁcantly increased the clonogeni-
city of treated-U266 cells in a Th2 cell:tumor cell ratio-dependent
manner (Figures 2a and c). In contrast, BCGV-Th2 cells had no
impact on the clonogenicity of untreated-U266 cells and K562
cells and U266 treated by IFN-g alone (Figures 2b, d and g), and
non-BCGV-speciﬁc Th2 cells and BCGV-speciﬁc CD8
þT cells had
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results were also observed not only in the assays of human
myeloma cell line RPMI8266 but also in the assays of U266 with
puriﬁed protein derivative or TTA instead of BCGV (see Supple-
mentary Figures 1–3). BCGV-Th2 cell-mediated enhancement of
tumor clonogenicity in this system required close contact between
tumor cells and Th2 cells, as the effect was not evident when the
two cell populations were separated by a Transwell membrane
(Figure 2e). Therefore, interactions of treated-MM cells and BCGV-
Th2 cells can directly promote MM clonogenicity. Additionally,
clonogenic assays showed that either BCGV-Th2 cells or DCs could
signiﬁcantly increase the clonogenicity of treated-U266 cells, but
the number of tumor colonies promoted by BCGV-Th2 cells was
higher than that of tumor colonies promoted by DCs (Figure 3a).
Bcl-6 expression in tumor colonies
Previous studies have suggested an important role for Bcl-6 in
survival and self-renewal of germinal center B cells. Thus, the
expression of Bcl-6 in these tumor cells was assessed by western
blotting and PCR analysis. Both results conﬁrmed that Bcl-6
expression was increased in colonies of Th2 cell-induced
tumor cells (Figure 4), suggesting an important role for Bcl-6
in the clonogenicity of treated-U266 cells. In tumor clonogenic
assay promoted by DCs versus by Th2 cells, western blotting
showed that expression of Bcl-6 produced by BCGV-Th2 cells
was stronger in tumor colonies than that of Bcl-6 produced by
DCs (Figure 3b).
The effect of blocking MHC and CD40 on the interaction between
Th2 cells and U266 cells
To gain insight into the role of MHC-II and CD40 in the interac-
tion between Th2 cells and U266 cells, MoAbs against MHC-II
(anti-HLA-DR MoAb) or CD40 were used to inhibit the enhance-
ment of BCGV-Th2 cell-stimulated clonogenicity of treated-U266
cells. Pretreatment with the antibodies reduced or abolished
the enhancement in clonogenicity (Figures 2a and 5). Likewise,
Figure 1. Surface Ags on U266 cells treated by IFN-g or BCGV. Surface HLA-DR, CD40, CD80, CD86 and CD54 on tumor cells were examined by
ﬂow cytometry. (a) Treatment of U266 cells with IFN-g for 48h markedly increased HLA-DR, CD40 and CD80 expression, but CD40 and CD80
expressions were at a low level; *Po0.05. U266 cells expressed high levels of CD86 and CD54. (b) Expression of HLA-DR, CD40 and CD80 was
signiﬁcantly increased by treating U266 cells with BCGV; *Po0.05.
Table 1. Expression of Surface HLA-DR, CD40 and CD80 on primary myeloma cell (%)
Patient No. HLA-DR CD40 CD80
Untreated IFN-g BCGV Untreated IFN-g BCGV Untreated IFN-g BCGV
1 9.8 22.8 16.3 21.8 35.7 28.6 2.2 4.5 4
2 12.4 18.7 17 5.6 19.2 10.4 3.6 8.2 4.7
3 17.5 46.6 28.9 40.4 50.3 47.5 3.8 6.2 4.6
4 10.2 26.1 19.5 6.6 23.3 11.8 11.3 24.4 15.4
5 6.4 22.5 10.3 23.6 35.9 29 2.1 5.2 2.9
6 8.2 15.9 11.2 16.5 26.8 19.8 3.5 8.4 5.8
7 4.5 16.2 10.1 2.4 5.6 3.9 1.7 3.9 2.4
8 15.6 28.2 21.8 22.1 40.6 29.6 3.6 10.8 6.2
9 7.4 22.9 15.3 12.8 30.2 17.7 6.3 10.4 8.1
Median 10.2 24.4 16.7 16.9 29.7 22 4.2 9.1 6
Abbreviations: BCGV, Bacillus Calmette–Guerin Vaccine; BM, bone marrow; IFN-g, interferon-g; PC, plasma cells.
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Bcl-6 expression (Figure 4). A mouse isotypic control IgG had no
effect (Figures 2a and 4). Therefore, MHC-II and CD40 are two key
molecules affecting Th2 cell–myeloma cell interactions.
Analysis of tumor colonies
The enhanced clonogenicity stimulated by BCGV-Th2 cells was
evidenced by an increase in the number and size of indivi-
dual colonies (Figures 5 and 6a), and the lower forward scatter of
Figure 2. Clonogenicity of human tumor cells. Colonies were enumerated microscopically after 2–3 weeks of culture. IFN-g and BCGV-treated
U266 cells were plated with or without BCGV-Th2 cells in a clonogenic assay at a ratio of 1:10 (tumor cells: 10000/well). Results are the
mean±s.e.m. (error bars) of the aggregate of three separate experiments; *Po0.05. (a) Th2 cells versus no Th2 cells. Clonogenicity was
signiﬁcantly enhanced by BCGV-Th2, but reduced by anti-HLA-DR or anti-CD40;
#Po0.05. (b, d, g) Untreated-U266 cells or K562 cells or U266
treated by IFN-g alone were not impacted by BCGV-Th2 cells. (c) Treated-U266 cells were plated with BCGV-Th2 cells at an increasing Th2
cell/tumor cell ratio in a clonogenic assay. Clonogenicity was increased by Th2 cells in a Th2 cell:tumor cell ratio-dependent manner.
(e) Requirement for cell–cell contact. BCGV-Th2 cells were either plated along with treated-tumor cells (Th2/tumor ratio of 10:1) or separated
from treated-tumor cells by a transwell insert membrane. Treated-tumor cells alone were plated in the clonogenic assay and counted as
before. (f) To test for allogeneic effects, non-Ag-Th2 or Ag-CD8
þT cells were plated with treated-tumor cells. Both non-Ag-Th2 and Ag-CD8
þT
cells had no impact on tumor clonogenicity.
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their size was smaller than that of non-Th2 cells-inducer tumor
cells (Figure 6b). These results suggest an effect on cloning
efﬁciency or survival. Moreover, we veriﬁed that CD40 and HLA-DR
were upregulated in a higher percentage of U266 cells after inter-
action with Th2 cells (Figure 6e). We further demonstrated that the
cloning efﬁciency was higher in tumor cells from Th2-induced
colonies, treated with IFN-g and BCGV, then cocultured with fresh
BCGV-Th2 cells again, than in tumor cells from Th2-induced
colonies, treated with IFN-g and BCGV without repeat coculture
with BCGV-Th2 cells (Figure 6c). The increase in cloning efﬁciency
was also reduced or abolished by culture in the presence of anti-
CD40 or anti-HLA-DR but not in the presence of mouse isotypic
control IgG (Figure 6c). In replating assays of clonogenicity, cells
from colonies of U266 cells (ﬁrst treated with IFN-g and BCGV for
48h and then induced by Th2 cells) had higher cloning efﬁciency
than U266 cells from suspension cultures in the same culture
medium with or without BCGV-Th2 cells (Figure 6d). Therefore,
Th2 cell-induced change in the biology of myeloma cells may
account for the increased ability of myeloma cells to form colonies.
Enhancement of clonogenicity of primary myeloma cells by
BCGV-Th2 cells
To extend these observations from U266 cells to primary myeloma
cells, bone marrow samples from patients with myeloma were
examined. Primary myeloma cells were cultured in the presence or
absence of autologous or allogeneic Th2 cells. The number of
tumor colonies formed by MNCs (primary myeloma cells from 12
patients, respectively) treated with IFN-g and BCGV and cocultured
with BCGV-Th2 cells was higher in 9/12 patients (6/8 patients
using allogeneic Th2 cells and 3/4 patients using autologous Th2
cells) than the number formed by same cells treated in the same
way but without MNC-Th2 cell coculture. This increase in tumor
colony number was reduced or abolished by the presence of anti-
CD40 or anti-HLA-DR in the culture (Figure 7). Therefore, BCGV-Th2
cells can also enhance the clonogenicity of treated-primary
myeloma cells.
DISCUSSION
The immune system may facilitate the growth of some tumors.
Several studies have suggested a role for tumor-associated DCs or
macrophages as a driver of growth in breast cancer, lymphoma
and myeloma.
11,18 As malignant myeloma cells are B cells or
plasma cells, we thought that Th2 cells probably promote
myeloma growth. Prior studies reported enhanced myeloma
growth after immunotherapy with tumor Ag-pulsed DCs.
3,11
However, our in vitro data indicated that Th2 cells do not
promote proliferation and clonogenicity of myeloma cells directly.
We think that the absence of MHC class II molecules and/or other
molecules on myeloma cell membrane may account for this
limitation. Promotion of tumor growth Th2 cells should require
myeloma cell expression of MHC class II molecules, costimulatory
molecules B7 (CD80, CD86), CD40, adhesion molecules (CD54) and
so on, which are required in Th2 cell-induced proliferation of
B cells.
19–26 Our studies showed that myeloma cells express
membrane markers of B cells including high levels of CD86 and
CD54 and detectable levels of HLA-DR, CD40 and CD80, which can
be upregulated by IFN-g. These data are consistent with the
ﬁndings of prior studies.
17 Surprisingly, we found that microbial
Ags, such as BCGV, TTA and so on, could induce expression of
MHC-II and CD40 on the myeloma cell surface. In our studies,
BCGV-speciﬁc Th2 cells induced by BCGV-loaded-DCs signiﬁ-
cantly enhanced the clonogenicity of myeloma cells induced to
express MHC-II, CD40 and CD80 by IFN-g and BCGV. These data
suggest that a small proportion of malignant plasma cells retain
B-cell functions, may possess stem cell characteristics, and
must interact with Th2 cells to form colonies. This malignant
plasma cell subpopulation may account for the development and
recrudescence of malignant plasma cell tumors.
In our studies, blockade of T-cell receptor (TCR)–MHC-II
interaction by anti-MHC-II MoAb or blockade of the CD40L–
CD40 interaction by anti-CD40 MoAb inhibited Th2 cell-mediated
enhancement of the clonogenicity of human myeloma cells,
suggesting that the Th2 cell–myeloma cell interaction is like the
Th2 cell–B-cell interaction in that CD40L ligands and TCR on the
Th2-cell surface recognize the speciﬁc Ag peptide borne by the
MHC-II on the myeloma cell. Prior studies have conﬁrmed that
Figure 3. BCL-6 expression of clonogenicity promoted by DCs versus
by Th2 cells. (a) IFN-g and BCGV-treated U266 cells were plated with
BCGV-Th2 cells or DCs in a clonogenic assay at a ratio of 1:10 (tumor
cells: 10000/well). Results are the mean±s.e.m. (error bars) of the
aggregate of three separate experiments; *Po0.05,
#Po0.05. (b) The
expression of Bcl-6 and b actin in U266 cells was analyzed by
western blotting.
Figure 4. Bcl-6 expression of U266 cells from colonies. (a) The
expression of Bcl-6 and b actin in U266 cells was analyzed by
western blotting. (b) The expression of Bcl-6 mRNA in U266 cells
was analyzed by SYBR Green I PCR and normalized to the expression
of the housekeeping gene, which was signiﬁcantly enhanced by
BCGV-Th2; *Po0.05, but reduced by anti-HLA-DR or anti-CD40;
#Po0.05.
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& 2012 Macmillan Publishers Limited Blood Cancer JournalFigure 5. Appearance of colonies of U266 cells. The clonogenicity assays were performed in methylcellulose. Treated-tumor cells were plated
with BCGV-Th2 cells (TumorþTh2), without BCGV-Th2 cells (tumor Alone), with BCGV-Th2 cells and anti-HLA-DR (Anti-HLA-DR), with BCGV-
Th2 cells and anti-CD40 (anti-CD40), with BCGV-Th2 cells and control IgG2b (control IgG2b). Micrographs show the appearance of colonies at
low power. (Upper panel) Appearance of colonies of treated-U266 cells (tumor cells: 10000/well). (Lower panel) Appearance of colonies of
tumor cells from bone marrow (tumor cells: 100000/well).
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to CD4
þT cells, which are MHC class-II restricted.
17 In our studies,
promotion of tumor colony formation by Th2 cells only occurred
if TCR recognized the speciﬁc Ag peptide bound to the MHC-II
of the tumor cell. The fact that anti-MHC-II MoAb abolished
the enhancement of tumor clonogenicity but anti-CD40 MoAb
merely reduced the enhancement indicates that tumor colony
growth promotion by Th2 cells is mainly MHC class-II restricted.
However, our data do not exclude the possibility that other
molecules such as adhesion molecules CD54 (CD54–CD11 a
interaction) or costimulatory molecules B7 (B7–CD28 interaction)
on myeloma cells may also be important in Th2 cell–myeloma
interactions. Th2-mediated regulation of myeloma growth may
also subvert Th1-cell-mediated immunity and require the partici-
pation of Th2-cell-derived cytokines, such as IL-4, IL-6 and IL-10.
In most cases, myeloma cells, like U266 cells, express almost no
Bcl-6.
11,27–29 However, in our study, Bcl-6 was highly expressed
in cells from Th2 cell-induced MM colonies. Normally, Bcl-6
contributes to the deﬁnition of the germinal center phenotype
by repressing multiple DNA damage and cell proliferation
checkpoint genes.
30–32 The level of Bcl-6 is downregulated
during the differentiation of B cells from memory B cells and
plasmablastic cells.
33 The Bcl-6-mediated loss of checkpoint
function may result in a potentially hazardous state of
physiological genomic instability, which may cause B cells to
undergo malignant transformation.
34–36 These ﬁndings are
consistent with the ﬁndings of a previous study that showed
the reactivation of the B-cell program after Bcl-6 was exogenously
expressed in myeloma cell lines.
37 So, it is concluded that
upregulation of Bcl-6 in myeloma cells may protect the cells
from apoptosis and idiovariability and thereby facilitate the
formation of malignant clones. We further observed that anti-
CD40 reduced but failed to abolish the upregulation of Bcl-6.
Therefore, other pathways besides the CD40 signaling pathway
should exist to promote Bcl-6 expression in Th2 cell-induced
tumor colonies. In our study, Bcl-6 expression was upregulated
and the percentages of HLA-DR
þ cells and CD40
þ cells were
higher in Th2 cell-induced tumor colonies, suggesting that the
differentiation state of myeloma cells is plastic and can be
modiﬁed by Th2 cell–myeloma cell interaction.
Microbial Ags are regarded as a potential cause of some tumors.
Prior studies have argued that carcinogenesis results from indirect
or direct interaction of inﬂammatory cells and mediators with
epithelial cells, stromal cells and extracellular matrix components,
Figure 6. Analysis of tumor colonies in clonogenic assays. (a) Colony diameter was measured in 100 random colonies per group after a 3-week
period of culture. The average diameter of colonies was signiﬁcantly larger in cocultures of tumor cells with Th2 cells than in cultures of tumor
cells without Th2 cells; *Po0.05. However, this increase was eliminated by anti-HLA-DR and anti-CD40;
#Po0.05. Results are the mean±s.e.m.
(error bars) of the aggregate of three separate experiments. (b) Flow cytometric analysis of the size of tumor cells in colonies after culture with
or without BCGV-Th2 cells for 3 weeks. (c, d) Replating assays of clonogenicity. The tumor cells from BCGV-Th2 cell-induced U266 colonies
treated again with IFN-g and BCGV for 48h and cocultured again with BCGV-Th2 cells for 3 weeks had higher cloning efﬁciency; *Po0.05.
However, anti-CD40 MoAb reduced and anti-HLA-DR MoAb abolished colony formation;
#Po0.05. Results are the mean±s.e.m. (error bars) of
the aggregate of three separate experiments. (e) Tumor colonies from clonogenic assays after a 3-week culture period were harvested and
stained with HLA-DR PE, CD40-FITC, CD4-FITC and Ig lambda FITC for ﬂow cytometric evaluation.
Figure 7. Clonogenicity of primary myeloma cells. Assay of cells from primary myeloma bone marrow samplesc (n¼12). Tumor cells were
cultured in the presence or absence of allogeneic (n¼8) or autologous Th2 cells (n¼4) at a ratio of 1:5 in the clonogenic assay. Patient 1
(tumor cells: 250000/well); Patient 3, 4, 8 and 9 (tumor cells: 100000/well); Patient 5, 10, 11 and 12 (tumor cells: 50000/well). Clonogenicity was
markedly enhanced by BCGV-Th2 cells, *Po0.05, but reduced by anti-HLA-DR or anti-CD40;
#Po0.05. (a) Clonogenicity was in six allogeneic
assays (6/8). (b) Clonogenicity was in three allogeneic assays (3/4).
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38–40 Nevertheless, the direct
effects of microbial Ags on tumor cells have not been well studied.
Unlike previous studies, our study showed that microbial Ags, such
as BCGV and TTA, enhance myeloma clonogenicity, not just the
level of humoral immunity.
12,17,41,42 To our knowledge, our
ﬁndings provide the ﬁrst evidence that microbial Ags presented
by APCs (DCs and myeloma cells) to Th2 cells cause malignant
plasma cell disease and participate in MM pathogenesis. In our
studies, we analyzed whether allogeneic Th2 cells or autogeneic
Th2 cells could drive myeloma cell colony formation, indicating
that Th2 cells may be one of the risk factors for patients with MM.
The result is consistent with previous reports that early stage and
non-advanced MM patients were with Th1 high proportion,
whereas advanced MM patients were with a predominated Th2-
like response in PBMC after stimulation by monoclonal IgG or
microbial Ags.
43–45 So, microbial Ags-Th2 cells may deeply involve
in pathogenesy, recurrence and development of MM. However,
our ﬁndings do not exclude other mechanisms of MM patho-
genesis. In conclusion, our study has presented evidence for a
novel mechanism of MM pathogenesis (that is, tumor generation
from a small number of MHC-II
þ malignant plasma cells with
B cell and stem cell characteristics that can form colonies efﬁci-
ently upon Th2-cell induction). Speciﬁcally, when the MHC-II
þ
malignant plasma cells take up microbial Ag they act as APCs.
DCs presenting the same microbial Ag activate Th2 cells to
recognize malignant plasma cells and induce them to proliferate
and form colonies. Thus, every factor involved in Ag presentation,
such as microbial Ags, DCs, Th2 cells and so on, may be potential
targets to be further studied for therapeutic intervention.
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